A Short Instrumented Test of Mobility for Neurological Disorders
神经系统疾病流动性的简短仪器测试
基本信息
- 批准号:8705232
- 负责人:
- 金额:$ 51.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:Admission activityAgeAgingAssisted Living FacilitiesAthleticBiological MarkersCessation of lifeClinicClinicalClinical DataClinical ResearchClinical TrialsCommunitiesComplexComputer softwareConsensusDataData CollectionDatabasesElderlyElderly manEquilibriumEvaluationFall preventionGaitGait abnormalityGoalsHospitalsHumanInjuryLaboratoriesLaboratory StudyLevodopaLinkLongitudinal StudiesMarketingMeasuresMetricMonitorMotionMovementMovement DisordersNeurologistNursing HomesOregonParkinson DiseasePatientsPenetrationPerformancePhasePrimary Care PhysicianProtocols documentationRecurrenceReference ValuesRehabilitation therapyReportingResearchResearch PersonnelSeveritiesSeverity of illnessSiteSmall Business Technology Transfer ResearchStep TestsSystemTechnologyTestingVisitWalkingWomanage relatedbaseclinical practicedisabilityequilibration disorderfall riskfallsinstrumentinterestkinematicsmennervous system disordernovelolder menolder womenosteoporosis with pathological fractureprospectivepublic health relevancesensortechnology development
项目摘要
DESCRIPTION (provided by applicant): APDM is a young company focused on developing and commercializing professional systems using wearable inertial sensors for monitoring of human movement and movement disorders. In Phase I, we developed the novel, Instrumented Stand and Walk test (ISAW) using APDM's proprietary, Opal movement monitors and Mobility Lab system. We validated the ISAW by demonstrating that the ISAW measures were sensitive to severity of Parkinson's disease (PD) and levodopa treatment. The ISAW allows clinicians and nonexperts to quickly obtain objective measures of standing balance, step-initiation, gait, and turning. The ultimate goal for the product is to provide a quick, portable, clinical system to quickly and automatically obtain objective measures of balance and gait disorders to predict fall risk using body-worn sensors. This Phase II STTR proposal will expand the use of the ISAW from PD to elderly fallers. We will partner with the largest, longitudinal study of falls in elderl men, the Osteoporotic Fractures in Men Study (MrOS), to characterize balance and gait in 361 community-dwelling older men, and with the Oregon Center of Aging and Technology (ORCATECH) in 97 community-dwelling older women. This proposal will not only demonstrate the feasibility and usefulness of the ISAW to quickly quantify balance and gait for multicenter clinical trials, it will also develop a unique Fall Risk Report and provide the ISAW with normative
values for the elderly. This 3-year study will have both a Clinical Research and a Technology Development Aim to prepare the ISAW to expand market penetration from research to clinical practice as an objective biomarker for fall risk and mobility disability. The impact of the ISAW wil be on clinicians interested in measuring fall risk in the elderly, including primary care physician, neurologists, geriatricians, rehabilitation professionals, assisted living facilities, hospitals an athletic trainers. The Specific Aims are: Aim I. Clinical Research: Develop a fall risk evaluation system for clinicians from the ISAW test (Milestone 1. Develop a Fall Risk Report and Milestone 2. Develop reference values for integrity of balance and gait across older ages). Aim II. Technology Development: Prepare the ISAW to be practical and attractive for clinical practice as well as clinical trials (Milestone 3. Mobility Exchange: Prepare data repository for multi-site clinical data collection from the ISAW test (Milestone 4. Mobility Clinic: Simplify user-interface and reporting for clinicians, and Milestone 5. FDA: Put quality systems and regulatory compliance in place so ISAW can be marketed for clinical practice). This Phase II proposal will transform APDM's ISAW protocol into the first technological system for clinicians (Mobility Clinic) and clinical researchers (Mobility Lab) to provide a validated, objective fall risk evaluation, as well as comprehensive balance and gait disorder assessment.
描述(申请人提供):APDM是一家年轻的公司,专注于开发和商业化使用可穿戴惯性传感器监测人体运动和运动障碍的专业系统。在第一阶段,我们使用APDM专有的Opal运动监测器和移动实验室系统开发了新颖的仪表式站立和行走测试(ISAW)。我们通过证明ISAW措施对帕金森病(PD)和左旋多巴治疗的严重程度敏感来验证ISAW。ISAW允许临床医生和非专家快速获得站立平衡、步态启动、步态和转身的客观测量。该产品的最终目标是提供一种快速、便携的临床系统,利用身体佩戴的传感器快速、自动地获得平衡和步态障碍的客观测量,以预测跌倒风险。这项第二阶段的短期租约建议,将会把ISAW的使用范围由帕金森病扩展至老年跌倒者。我们将与最大的关于老年男性跌倒的纵向研究,男性骨质疏松性骨折研究(MROS)合作,以确定361名社区居住的老年男性的平衡和步态特征,并与俄勒冈州老龄化与技术中心(ORCATECH)合作,研究97名社区居住的老年女性的平衡和步态。这项建议不仅将证明ISAW在多中心临床试验中快速量化平衡和步态的可行性和有用性,它还将制定独特的跌倒风险报告,并为ISAW提供规范的
老年人的价值观。这项为期3年的研究将以临床研究和技术开发为目标,为ISAW做好准备,将市场渗透率从研究扩大到临床实践,作为跌倒风险和行动不便的客观生物标记物。ISAW将对有兴趣测量老年人跌倒风险的临床医生产生影响,包括初级保健医生、神经科医生、老年医生、康复专业人员、辅助生活设施、医院和运动教练员。具体目标是:目标1.临床研究:根据ISAW测试为临床医生开发跌倒风险评估系统(里程碑1.制定跌倒风险报告和里程碑2.制定老年人平衡和步态完整性的参考值)。目的II.技术开发:使ISAW具有实用性和临床试验的吸引力(里程碑3.移动性交换:为从ISAW测试中收集的多点临床数据准备数据储存库(里程碑4.移动诊所:简化临床医生的用户界面和报告,里程碑5.FDA:建立质量体系和法规遵从性,以便ISAW可用于临床实践)。这项第二阶段的提案将把APDM的ISAW协议转变为临床医生(移动诊所)和临床研究人员(移动实验室)的第一个技术系统,以提供经过验证的、客观的跌倒风险评估,以及全面的平衡和步态障碍评估。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mahmoud El-Gohary其他文献
Mahmoud El-Gohary的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mahmoud El-Gohary', 18)}}的其他基金
Home biofeedback (VibroGait) for people with impaired somatosensation
针对体感受损人士的家庭生物反馈 (VibroGait)
- 批准号:
10011639 - 财政年份:2020
- 资助金额:
$ 51.32万 - 项目类别:
Mobility Life: Monitoring Mobility in Daily Lives of People with Neurological Disease
移动生活:监测神经系统疾病患者日常生活中的移动能力
- 批准号:
9202863 - 财政年份:2016
- 资助金额:
$ 51.32万 - 项目类别:
Mobility Life: Monitoring Mobility in Daily Lives of People with Neurological Disease
移动生活:监测神经系统疾病患者日常生活中的移动能力
- 批准号:
9523322 - 财政年份:2016
- 资助金额:
$ 51.32万 - 项目类别:
Monitoring Balance and Gait Disorders in Parkinson???s Disease with the Home Obje
使用 Home Obje 监测帕金森病的平衡和步态障碍
- 批准号:
8665857 - 财政年份:2013
- 资助金额:
$ 51.32万 - 项目类别:
Home Objective Mobility Exam (HOME) for Balance and Gait Disorders in Parkinson's
主页 针对帕金森病平衡和步态障碍的目标行动能力检查 (HOME)
- 批准号:
8519026 - 财政年份:2013
- 资助金额:
$ 51.32万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The Phenomenon of Stem Cell Aging according to Methylation Estimates of Age After Hematopoietic Stem Cell Transplantation
根据造血干细胞移植后甲基化年龄估算干细胞衰老现象
- 批准号:
23K07844 - 财政年份:2023
- 资助金额:
$ 51.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of Age-dependent Functional Changes in Skeletal Muscle CB1 Receptors by an in Vitro Model of Aging-related Muscle Atrophy
通过衰老相关性肌肉萎缩的体外模型分析骨骼肌 CB1 受体的年龄依赖性功能变化
- 批准号:
22KJ2960 - 财政年份:2023
- 资助金额:
$ 51.32万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Joint U.S.-Japan Measures for Aging and Dementia Derived from the Prevention of Age-Related and Noise-induced Hearing Loss
美日针对预防与年龄相关和噪声引起的听力损失而导致的老龄化和痴呆症联合措施
- 批准号:
23KK0156 - 财政年份:2023
- 资助金额:
$ 51.32万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
The Effects of Muscle Fatigability on Gait Instability in Aging and Age-Related Falls Risk
肌肉疲劳对衰老步态不稳定性和年龄相关跌倒风险的影响
- 批准号:
10677409 - 财政年份:2023
- 资助金额:
$ 51.32万 - 项目类别:
Characterizing gut physiology by age, frailty, and sex: assessing the role of the aging gut in "inflamm-aging"
按年龄、虚弱和性别表征肠道生理学特征:评估衰老肠道在“炎症衰老”中的作用
- 批准号:
497927 - 财政年份:2023
- 资助金额:
$ 51.32万 - 项目类别:
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
- 批准号:
10679287 - 财政年份:2023
- 资助金额:
$ 51.32万 - 项目类别:
Role of AGE/RAGEsignaling as a driver of pathological aging in the brain
AGE/RAGE信号传导作为大脑病理性衰老驱动因素的作用
- 批准号:
10836835 - 财政年份:2023
- 资助金额:
$ 51.32万 - 项目类别:
Elucidation of the protein kinase NLK-mediated aging mechanisms and treatment of age-related diseases
阐明蛋白激酶NLK介导的衰老机制及年龄相关疾病的治疗
- 批准号:
23K06378 - 财政年份:2023
- 资助金额:
$ 51.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Underlying mechanisms of age-related changes in ingestive behaviors: From the perspective of the aging brain and deterioration of the gustatory system.
与年龄相关的摄入行为变化的潜在机制:从大脑老化和味觉系统退化的角度来看。
- 批准号:
23K10845 - 财政年份:2023
- 资助金额:
$ 51.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeting Age-Activated Proinflammatory Chemokine Signaling by CCL2/11 to Enhance Skeletal Muscle Regeneration in Aging
通过 CCL2/11 靶向年龄激活的促炎趋化因子信号传导以增强衰老过程中的骨骼肌再生
- 批准号:
478877 - 财政年份:2023
- 资助金额:
$ 51.32万 - 项目类别:
Operating Grants